E
CADL icon

Ergoteles’s Candel Therapeutics CADL Stock Holding History

Ergoteles’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,416
Closed -$15.6K – 1083
2023
Q1 		$15.6K Sell
11,416
-14,698
-56% -$28.7K ﹤0.01% 1163
2022
Q4 		$46.7K Buy
+26,114
New +$51.7K ﹤0.01% 1301

Other funds holding CADL

NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BWM
Baystate Wealth Management Boston, Massachusetts $1.36B AUM 15.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ergoteles's CADL Position: Q2 2023 in Review

Ergoteles sold out of Candel Therapeutics (CADL) in Q2 2023, closing a stake of 11,416 shares — an estimated $15.6K sold.

Ergoteles first reported a position in CADL in Q4 2022 and held it in 2 quarters. The position peaked at $46.7K in Q4 2022. 20 funds tracked by Wall St. Rank hold CADL as of Q2 2023.

  • Ergoteles reported no remaining Candel Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 11,416 Candel Therapeutics shares in Q2 2023, an estimated $15.6K.
  • Ergoteles first reported a position in Candel Therapeutics in Q4 2022 and held it in 2 quarters.
  • Ergoteles's Candel Therapeutics position peaked at $46.7K in Q4 2022.
  • 20 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.